“Google is Betting $1.2B on These 5 Crashing Stocks 🚨”
$OBXNo side taken
AI summary · Obsidian is a speculative early-stage investment, hard to evaluate, with potential for significant gains but significant risk if its flagship drug cannot reach the market; revenue is almost nil with losses in the hundreds of millions, while $350 million raised should fund it through 2027 trial results. The speaker does not own it and will follow it on a watchlist.
We begin with a small clinical-stage biotechnology company called Obsidian Therapeutics, ticker symbol OBX, which Google, according to documents, has added to its investment portfolio with an investment of approximately $16.8 million.
To clarify, this is not a sudden decision by Google to day-splurge on cheap biotech stocks. Obsidian went public in August through a reverse merger with a struggling biotech company called Galera Therapeutics, in which Google’s early investment arm had a private investment.
That company whose shares have now been converted to public shares.
What they said to watch for